Evolus Past Earnings Performance

Past criteria checks 0/6

Evolus has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 43.3% per year.

Key information

6.1%

Earnings growth rate

22.0%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate43.3%
Return on equity-325.3%
Net Margin-27.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10
The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16
Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04
Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21
Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Evolus (NASDAQ:EOLS) Has Debt But No Earnings; Should You Worry?

Sep 11
Evolus (NASDAQ:EOLS) Has Debt But No Earnings; Should You Worry?

Revisiting Evolus

Sep 09

Revenue & Expenses Breakdown

How Evolus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:EOLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24220-601737
31 Dec 23202-621657
30 Sep 23185-631596
30 Jun 23169-661505
31 Mar 23156-721466
31 Dec 22149-741425
30 Sep 22140-791384
30 Jun 22132-791353
31 Mar 22121-711252
31 Dec 21100-471122
30 Sep 2186-1391062
30 Jun 2177-131962
31 Mar 2158-137882
31 Dec 2057-163982
30 Sep 2055-671011
30 Jun 2051-821102
31 Mar 2045-991272
31 Dec 1935-901144
30 Sep 1915-88955
30 Jun 192-73716
31 Mar 190-52427
31 Dec 180-47286
30 Sep 180-30197
30 Jun 180-21136
31 Mar 180-776
31 Dec 170-457
30 Sep 170-1348
30 Jun 170-14410
31 Mar 170-18612
31 Dec 160-20713

Quality Earnings: EOLS is currently unprofitable.

Growing Profit Margin: EOLS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EOLS is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.

Accelerating Growth: Unable to compare EOLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EOLS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).


Return on Equity

High ROE: EOLS has a negative Return on Equity (-325.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.